SAB4200534
Anti-Claudin-1 (C-terminal) antibody produced in rabbit
~1.0 mg/mL, affinity isolated antibody
别名:
Anti-Claudin-1 (C-Terminal), antibody produced in rabbit, affinity isolated antibody
产品名称
Anti-Claudin-1 (C-terminal) antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~23 kDa
species reactivity
human, dog
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
concentration
~1.0 mg/mL
technique(s)
immunohistochemistry: 20 μg/mL using formalin-fixed, paraffin-embedded human colon.
indirect immunofluorescence: 1.0-2.0 μg/mL using MDCK cells.
western blot: 0.5-1.0 μg/mL using extracts of HEK-293T cells overexpressing human claudin-1.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CLDN1(9076)
Application
Anti-Claudin-1 (C-terminal) antibody produced in rabbit has been used in:
- immunoblotting
- immunofluorescence
- immunohistochemistry
Biochem/physiol Actions
Claudin-1 directly interacts with tight junction (TJ) -associated peripheral membrane proteins zonula occludens (ZO) proteins -1/2/3. Defects in the gene encoding claudin-1 are the cause of an autosomal recessive syndrome named ichthyosis-sclerosing cholangitis neonatal (NISCH). Claudins′ expression is altered in several human cancers. Claudin-1 is frequently up-regulated in colorectal carcinomas (CRCs), resulting in tumor differentiation and progression.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Claudin-1, also known as claudin 1 (CLDN1), seminal metalloprotease-1 (Semp1) and ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis (ILVASC), is expressed at high levels in kidney and liver and at lower levels in spleen, heart, brain, lung and testis. Claudins are characterized with four transmembrane domains and two extracellular loops, required to form tight junction strands.
Immunogen
synthetic peptide corresponding to a sequence at the C-terminus of human claudin-1, conjugated to KLH. The corresponding sequence is highly conserved in mouse claudin-1 (single amino acid substitution) and in rat claudin-1 (90% identity).
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Claudin-1 involved in neonatal ichthyosis sclerosing cholangitis syndrome regulates hepatic paracellular permeability
Yuan P, et al.
Cell research, 25, 157-168 (2014)
Transmembrane Proteins in the Tight Junction Barrier
Fanning A S, et al.
Journal of the American Society of Nephrology, 10, 1337-1345 (1999)
Nga Le et al.
Cellular and molecular gastroenterology and hepatology, 11(1), 55-76 (2020-07-14)
Communication between T cells and the intestinal epithelium is altered in many diseases, causing T-cell activation, depletion, or recruitment, and disruption of the epithelium. We hypothesize that activation of T cells regulates epithelial barrier function by targeting the assembly of
Pengfei Yuan et al.
Cell research, 25(2), 157-168 (2014-12-31)
As a gram-positive, spore-forming anaerobic bacillus, Clostridium difficile (C. difficile) is responsible for severe and fatal pseudomembranous colitis, and poses the most urgent antibiotic resistance threat worldwide. Epidemic C. difficile is the leading cause of antibiotic-associated diarrhoea globally, especially diarrhoea
Angélica Cruz-Lebrón et al.
Gut microbes, 13(1), 1946368-1946368 (2021-07-28)
Over the past three decades the United States has experienced a devastating opioid epidemic. One of the many debilitating side effects of chronic opioid use is opioid-induced bowel dysfunction. We investigated the impact of methadone maintenance treatment (MMT) on the
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持